Orally active GH secretagogues and the endogenous peptide cortistatin both target the ghrelin receptor, with cortistatin's cross-reactivity revealing additional therapeutic dimensions beyond GH release and appetite.
Multi-ligand receptorThe ghrelin receptor responds to ghrelin, synthetic GHS, AND cortistatin — a richer pharmacology than one ligand would suggest
What the researchers found
Orally active GH secretagogues and cortistatin (a somatostatin-related peptide) both target the ghrelin receptor, expanding the receptor's known ligand repertoire and therapeutic targeting possibilities.
Why it matters
The ghrelin receptor integrates signals from multiple peptide families. Understanding this broader ligand landscape improves drug design and predicts clinical effects more accurately.
How the study worked
Review of oral GH secretagogue development (peptide and non-peptide) and the emerging pharmacology of cortistatin-GHS-R interaction.
What this study cannot tell us
Review from 2003. The clinical significance of cortistatin-GHS-R interaction was still being explored.
How to read the evidence
Moderate evidence from a review integrating drug development data with novel receptor pharmacology.
When this study was published
Published in 2003. The cortistatin-ghrelin receptor interaction has been further characterized.
The bigger picture
Receptors rarely respond to just one ligand in nature. The ghrelin receptor's response to both ghrelin and cortistatin reveals a richer signaling system than assumed.
Questions still open
- Does cortistatin modulate ghrelin's appetite effects?
- Could cortistatin analogs be developed for specific GHS-R therapeutic targeting?
- Do cortistatin levels affect GH secretagogue drug efficacy?
Common questions
What is cortistatin?
Why does this matter for drug development?
Read the original research
Targeting the ghrelin receptor: orally active GHS and cortistatin analogs.
Endocrine, 22(1), 13-8
Citation
Deghenghi, Romano; Broglio, Fabio; Papotti, Mauro; Muccioli, Giampiero; Ghigo, Ezio. (2003). Targeting the ghrelin receptor: orally active GHS and cortistatin analogs.. Endocrine, 22(1), 13-8.